Evercyte extracellular vesicle (EV) production

Evercyte produces standardized research grade extracellular vesicles (EVs) that play essential roles as transporters of proteins, lipids and nucleic acids in cellular communication.

EVs appear to exert protective effects by transferring endogenous molecules to salvage injured neighboring cells by regulating apoptosis, inflammation, fibrosis and angiogenesis, which has made them the focus for biomedical research seeking new therapies for various diseases.

Evercyte’s clinical research-grade EVs and exosomes can be used for a wide range of applications including preclinical research, potency assays, functional studies is areas such as wound healing, inflammation, and tissue regeneration, and in developing innovative drug delivery and targeting systems.

EV production

Evercyte has developed protocols for the isolation and expansion of human cells, especially mesenchymal stem cells from different origins.

Evercyte not only offers cell factories for production of exosomes but also off-the-shelf extracellular vesicles from different mesenchymal stem cells such as from Wharton´s Jelly (WJ-MSC/TERT273). These EVs are characterized by anti-inflammatory, neo-angiogenic and fibroblast growth-promoting activities, making them, ideal for various EV research applications.  Evercyte also offers appropriate cell culture media to accompany its cell lines.

Evercyte mesenchymal stem cell lines from umbilical cord, bone marrow, endometrium or adipose tissue can be used for production of extracellular vesicles for R&D. After transfer to GMP environment, the cells can also be used for production of clinical grade extracellular vesicles as these cell lines have been established under xeno-free conditions, non-virally and full documentation of any manipulation step.

Extracellular vesicles are released by cells and play an important role in cellular communication due to their capacity to transport proteins, lipids as well as nucleic acids. As such, they are gaining ever increasing importance in the fields of regenerative and transplant medicine, anti-tumor therapy as well as immunotherapy.

Differentiated exosomes

Exosomes defy imaging by conventional methods, being released only sporadically and too small to be seen by fluorescence microscopy. It is possible to see exosome release occurring in cell cultures using exosome electron microscopy but the main method of isolation is to pool exosomes from cellular supernatant or animal fluids, using differential centrifugation.

Evercyte uses human highly differentiated cell lines from different organs and tissues for EV / exosome production. It can establish cell lines for production of clinical grade EVs as a one-stop-solution, encompassing tissue sourcing, ethical approval, primary cell culture, life-span extension, and  detailed exosome characterization of cells and secreted EVs.

Evercyte capabilities includes exosome characterization studies (miRNA profiling, proteomics, surface marker profiling, electron microscopy).

Standardized human cell EVs

Evercyte EV sources are human cells from different tissues (e.g. umbilical cord, bone marrow, endometrium) with cellular life span elongated by reactivation of human telomerase and cells characterized for expression of cell type specific markers and functions as well as freedom from contaminations (bacterial, fungi, human pathogenic viruses, cross-contaminations) and STR profiled for authenticity.

Principal production platforms include Wharton´s Jelly-derived MSCs established under xeno-free culture conditions, fully documented and bone marrow derived cells with high therapeutic potential of secreted EVs.

Currently EVs (Catalog EV-059-0273) from telomerized Wharton ́s Jelly derived mesenchymal stem cells grown in a hollow fiber bioreactor are readily available, enriched from cell culture supernatants using tangential flow filtration (TFF). All exosome production and exosome purification processes are carried out in a sterile environment. EVs from other cell cultures are produced upon customer request.

Benefits of Evercyte standardized EVs

Using Evercyte standardized human mesenchymal stem cells as factories for EV production delivers specific benefits in that the EVs, when produced under GMP conditions also qualify for clinical application as exosome production cell lines have been established following current standards for exosome production cell line establishment for regulatory acceptance.

Exosome production cell lines are isolated from human derived tissues with ethical approval by the responsible IRB and with prior given written informed consent.  These lines are established using xeno-free culture media and reagents, non-viral gene transfer methods and full documentation of all manipulation steps.

Resources

Click on Extracellular vesicles and media for more information.
Click on Evercyte EV-059-0273 to download product data sheet.